Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04540861
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
Phase 1
Completed
- Conditions
- Progressive Supranuclear Palsy (PSP)
- Interventions
- Drug: antisense oligonucleotideDrug: placebo
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT04539041
- Locations
- ๐บ๐ธ
University of California San Diego, La Jolla, California, United States
๐บ๐ธMayo Clinic Rochester, Rochester, Minnesota, United States
๐บ๐ธVanderbilt University Medical CenterX, Nashville, Tennessee, United States
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Phase 2
Active, not recruiting
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT04524000
- Locations
- ๐ฏ๐ต
Novartis Investigative Site, Niigata, Japan
Nilotinib, for Patients With CML-CP or CML-AP
- Conditions
- Chronic Myelogenous Leukemia (CML)
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04518644
Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy
Phase 3
Active, not recruiting
- Conditions
- Biallelic RPE65 Mutation-associated Retinal Dystrophy
- Interventions
- Genetic: voretigene neparvovec
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT04516369
- Locations
- ๐ฏ๐ต
Novartis Investigative Site, Meguro-ku, Tokyo, Japan
Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria
Phase 1
Terminated
- Conditions
- Chronic Spontaneous UrticariaCholinergic UrticariaCold Urticaria
- Interventions
- Drug: PlaceboDrug: Ligelizumab
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 11
- Registration Number
- NCT04513548
- Locations
- ๐ฉ๐ช
Novartis Investigative Site, Berlin, Germany
Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer
- Conditions
- Small Cell Lung Carcinoma
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04507919
MAP to Provide Access to Nilotinib, for Patients With HES
- Conditions
- Hypereosinophilic Syndrome (HES)
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04498871
Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)
Phase 4
Terminated
- Conditions
- Heart Failure
- Interventions
- Drug: ACEI/ARBDrug: ARNI
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 201
- Registration Number
- NCT04491136
- Locations
- ๐จ๐ณ
Novartis Investigative Site, Tianjin, China
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
- Conditions
- Melanoma
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04489433
ยฉ Copyright 2025. All Rights Reserved by MedPath